Diabetes is a disease characterized by an excess of sugar (glucose) in the blood. This condition is called hyperglycemia. The cause of hyperglycemia may be inadequate action or insufficient production of insulin, the hormone that regulates blood glucose levels. The main forms of diabetes are type 1 diabetes, with absence of insulin secretion, and type 2 diabetes resulting from reduced sensitivity of the body to insulin normally produced by the target tissues (liver, muscle and adipose tissue) and/or reduced insulin secretion in the pancreas (from cells called beta-cells).
Type 2 diabetes is a disease with high prevalence worldwide and its prevalence is constantly increasing. The causes of the disease include an interaction between genetic factors (familiarity) and environmental factors (sedentary life, eating habits, etc.).
La classificazione ufficiale prevede:
- type 1:diabetes characterized by beta-cellular destruction, on an autoimmune or idiopathic basis, leading to absolute insulin deficit
- type 2: insulin secretion defect, which can progressively worsen over time and is established on a pre-existing condition of insulin resistance
- other types of diabetes: genetic defects of beta-cellular function or insulin action, diseases of the pancreas exocrine, drug-induced or chemical-induced.
- gestational diabetes: which arises during pregnancy.
The Endocrino-Metabolic Department of the MultiMedica Group
MultiMedica with its facilities in Lombardia is characterized by the multidisciplinary management of diabetes pathology, whose nursing and dietary team makes use of clinics dedicated to the innovative therapy of diabetes type 2, diabetes gravidarum, diabetes type 1 with its many technological innovations. The team works in close collaboration with the highest expertise in the prevention and management of complications, including the Diabetic Foot Operating Unit, outpatient dyslipidemia outpatient activity, as well as specialist cardiology, nephrology and eye care outpatient clinics with routes identified according to the latest guidelines. Moreover, MultiMedica as IRCCS is home to clinical studies on the most important novelties in terms of research and treatment for metabolic diseases.